BASEIMMUNE LTD

Active London

Research and experimental development on biotechnology

17 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
B

BASEIMMUNE LTD

Research and experimental development on biotechnology

Founded 30 Oct 2019 Active London, England 17 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Due 30 Sept 2026 5 months remaining
Confirmation Submitted 12 Nov 2025 Next due 12 Nov 2026 6 months remaining
Net assets £10M £8M 2024 year on year
Total assets £10M £7M 2024 year on year
Total Liabilities £66K £342K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

The London Bioscience Innovation Centre Royal College Street London NW1 0NH England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for BASEIMMUNE LTD (12289125), an active life sciences and medical technology company based in London, England. Incorporated 30 Oct 2019. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2020–2024)

Cash in Bank

£8.66M

Increased by £6.91M (+393%)

Net Assets

£9.62M

Increased by £7.60M (+376%)

Total Liabilities

£65.68k

Decreased by £342.29k (-84%)

Turnover

N/A

Employees

17

Increased by 6 (+55%)

Debt Ratio

1%

Decreased by 16 (-94%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (8)

Investor NameInvestor SinceParticipating Rounds
Investor 4Apr 2021Series A, Seed
Investor 6Apr 2021Series A, Seed
Investor 8Apr 2021Seed

Share Capital

Share Capital

Share allotments and capital structure

12 Allotments 483,271 Shares £313228.45m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
1 Oct 20254,817£0.048£0
24 Aug 202574£0.01£0.01
24 Aug 202574£0.01£0.01
6 Dec 20242,126£6k£3
5 Jan 2024176,676£7.29m£41.26

Officers

Officers

2 active 1 resigned
Status
James Oliver MacfarlaneDirectorBritishUnited Kingdom3717 Mar 2021Active
Joshua Miles BlightDirectorBritishEngland3430 Oct 2019Active

Shareholders

Shareholders (34)

Joshua Miles Blight
13.1%
100,000
Phillip James Gordon Kemlo
13.1%
100,000

Persons with Significant Control

Persons with Significant Control (3)

3 Active

Philip James Gordon Kemlo

British

Active
Notified 30 Oct 2019
Residence England
DOB October 1990
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent,right To Appoint And Remove Directors

Ariane Karla Cruz Gomes

Brazilian

Active
Notified 30 Oct 2019
Residence England
DOB February 1991
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent,right To Appoint And Remove Directors

Joshua Miles Blight

British

Active
Notified 30 Oct 2019
Residence England
DOB June 1991
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
12 Nov 2025Confirmation StatementConfirmation statement made on 2025-10-29 with updates
12 Nov 2025OfficersChange to director Dr Joshua Miles Blight on 2025-09-23
12 Nov 2025OfficersAppointment of Kevin John Davlin Walton as director on 2025-09-23
12 Nov 2025OfficersChange to director Ms Philip James Gordon Kemlo on 2025-09-23
7 Nov 2025CapitalCapital Cancellation Shares
12 Nov 2025 Confirmation Statement

Confirmation statement made on 2025-10-29 with updates

12 Nov 2025 Officers

Change to director Dr Joshua Miles Blight on 2025-09-23

12 Nov 2025 Officers

Appointment of Kevin John Davlin Walton as director on 2025-09-23

12 Nov 2025 Officers

Change to director Ms Philip James Gordon Kemlo on 2025-09-23

7 Nov 2025 Capital

Capital Cancellation Shares

Recent Activity

Latest Activity

Confirmation statement made on 2025-10-29 with updates

5 months ago on 12 Nov 2025

Change to director Dr Joshua Miles Blight on 2025-09-23

5 months ago on 12 Nov 2025

Appointment of Kevin John Davlin Walton as director on 2025-09-23

5 months ago on 12 Nov 2025

Change to director Ms Philip James Gordon Kemlo on 2025-09-23

5 months ago on 12 Nov 2025

Capital Cancellation Shares

5 months ago on 7 Nov 2025